Updated recommendations from the PREFER project

After receiving the positive qualification opinion from the European Medicines Agency's (EMA) committee responsible for human medicines CHMP, we updated our recommendations. The new 1_1 version was published on 30 May, with minor edits, pointing to the feedback we received. 

Want to know more? Download the updated version from Zenodo, and have a look at the qualification opinion!

CITE AS: The PREFER consortium. (2022). PREFER Recommendations - Why, when and how to assess and use patient preferences in medical product decision-making. Zenodo. https://doi.org/10.5281/zenodo.6491042

(Image removed)

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).